X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Torrent Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs TORRENT PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB TORRENT PHARMA DR. REDDYS LAB/
TORRENT PHARMA
 
P/E (TTM) x 30.3 28.7 105.4% View Chart
P/BV x 3.0 5.5 54.3% View Chart
Dividend Yield % 0.9 1.0 91.3%  

Financials

 DR. REDDYS LAB   TORRENT PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
TORRENT PHARMA
Mar-17
DR. REDDYS LAB/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs3,3971,768 192.1%   
Low Rs2,5601,186 215.9%   
Sales per share (Unadj.) Rs856.5346.1 247.5%  
Earnings per share (Unadj.) Rs78.055.2 141.3%  
Cash flow per share (Unadj.) Rs139.973.3 190.8%  
Dividends per share (Unadj.) Rs20.0014.00 142.9%  
Dividend yield (eoy) %0.70.9 70.8%  
Book value per share (Unadj.) Rs739.8257.1 287.8%  
Shares outstanding (eoy) m165.74169.22 97.9%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.54.3 81.5%   
Avg P/E ratio x38.226.8 142.7%  
P/CF ratio (eoy) x21.320.1 105.7%  
Price / Book Value ratio x4.05.7 70.1%  
Dividend payout %25.725.4 101.1%   
Avg Mkt Cap Rs m493,632249,887 197.5%   
No. of employees `00022.711.8 192.5%   
Total wages/salary Rs m31,0689,934 312.7%   
Avg. sales/employee Rs Th6,259.04,971.5 125.9%   
Avg. wages/employee Rs Th1,369.8843.2 162.4%   
Avg. net profit/employee Rs Th569.7792.4 71.9%   
INCOME DATA
Net Sales Rs m141,96158,569 242.4%  
Other income Rs m1,7152,233 76.8%   
Total revenues Rs m143,67660,802 236.3%   
Gross profit Rs m24,72213,773 179.5%  
Depreciation Rs m10,2663,069 334.5%   
Interest Rs m6342,056 30.8%   
Profit before tax Rs m15,53710,881 142.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,9651,545 191.9%   
Profit after tax Rs m12,9219,336 138.4%  
Gross profit margin %17.423.5 74.1%  
Effective tax rate %19.114.2 134.4%   
Net profit margin %9.115.9 57.1%  
BALANCE SHEET DATA
Current assets Rs m96,83753,841 179.9%   
Current liabilities Rs m84,19931,612 266.4%   
Net working cap to sales %8.938.0 23.5%  
Current ratio x1.21.7 67.5%  
Inventory Days Days7397 75.5%  
Debtors Days Days9884 116.6%  
Net fixed assets Rs m102,55242,079 243.7%   
Share capital Rs m829846 98.0%   
"Free" reserves Rs m121,79242,655 285.5%   
Net worth Rs m122,62143,501 281.9%   
Long term debt Rs m5,44922,408 24.3%   
Total assets Rs m218,165101,250 215.5%  
Interest coverage x25.56.3 405.3%   
Debt to equity ratio x00.5 8.6%  
Sales to assets ratio x0.70.6 112.5%   
Return on assets %6.211.3 55.2%  
Return on equity %10.521.5 49.1%  
Return on capital %12.919.6 65.7%  
Exports to sales %54.60-   
Imports to sales %9.40-   
Exports (fob) Rs m77,520NA-   
Imports (cif) Rs m13,274NA-   
Fx inflow Rs m81,67020,066 407.0%   
Fx outflow Rs m26,3555,304 496.9%   
Net fx Rs m55,31514,762 374.7%   
CASH FLOW
From Operations Rs m21,44410,127 211.8%  
From Investments Rs m-18,404-7,869 233.9%  
From Financial Activity Rs m-3,692-1,918 192.5%  
Net Cashflow Rs m-1,144212 -540.9%  

Share Holding

Indian Promoters % 25.5 71.5 35.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 7.0 76.9%  
FIIs % 35.3 12.6 280.2%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 8.8 173.9%  
Shareholders   75,885 26,511 286.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   SUVEN LIFE  SHASUN PHARMA  SANOFI INDIA  TTK HEALTHCARE  SUN PHARMA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Losses; Capital Goods Sector Down 1.7%(11:30 am)

Indian share markets are presently trading on a negative note. Sectoral indices are trading in the red with stocks in the capital goods sector and metal sector witnessing maximum selling pressure.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Feb 19, 2018 11:57 AM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS